KIST Transfers ‘Dry Macular Degeneration Peptide Therapy’ Technology to Huons Bio
The Korea Institute of Science and Technology (KIST, President Oh Sang-rok) held a technology transfer signing ceremony on the 17th at the KIST headquarters in Seongbuk-gu, Seoul, with Huons Biopharma (CEO Kim Young-mok) for the development of a peptide therapeutic for dry age-related macular degeneration.
Under this agreement, the two institutions plan to conduct collaborative research over the next 14 months to accelerate the commercialization of peptide therapy technology for dry age-related macular degeneration targeting the elderly.
President Oh Sang-rok stated, “The collaboration between KIST and Huons Biopharma will serve as a representative example of the BP Plus project, which actively supports the commercialization process of companies that have signed technology transfer contracts.”
Kim Young-mok, CEO of Huons Biopharma, said, “We will work closely with KIST to advance global clinical trials for innovative dry age-related macular degeneration drugs and obtain product approval.”
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Don't Throw Away Coffee Grounds" Transformed into 'High-Grade Fuel' in Just 90 Seconds [Reading Science]
- Signed Without Viewing for 1.6 Billion Won... Jamsil and Seongbuk Jeonse Prices Jump 200 Million Won in a Month [Real Estate AtoZ]
- "Groups of 5 or More Now Restricted"... Unrelenting Running Craze Leaves Citizens and Police Exhausted
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
Huons Biopharma is a subsidiary of the Huons Group engaged in bio-businesses such as botulinum toxin. It was established in 2021 through a spin-off of the bio-business division of Huons Global.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
